Differentiated Thyroid CancerNCT07115810
No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid Cancer: Insight From Middle Eastern Cohort
An observational study of Differentiated Thyroid Cancer, run by King Faisal Specialist Hospital & Research Center.
Trial summary
The goal of this observational study is to compare the clinical outcomes, molecular features, and immune profiles of patients with synchronous and metachronous distant metastases in Saudi cohort with well characterized differentiated thyroid cancer. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Differentiated Thyroid Cancer
- How many people
- 178 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 1988to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Patients with metastatic differentiated thyroid cancer diagnosed at King Faisal Specialist Hospital \& Research Centre in Riyadh, Saudi Arabia
Who may be able to join
- Synchronous or metachronous distant metastases
Who cannot join
- Not DTC
- No distant metastases
About this study
The goal of this observational study is to compare the clinical outcomes, molecular features, and immune profiles of patients with synchronous and metachronous distant metastases in Saudi cohort with well characterized differentiated thyroid cancer. The main question it aims to answer is whether timing of metastasis is associated with distinct prognostic or biological behavior in differentiated thyroid cancer from a large Middle Eastern cohort
- Conditions
- Differentiated Thyroid Cancer
- Being tested
- No additional drugs(control Group)
- Keywords
- synchronous metastasis, metachronous metastasis, prognosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No additional drugs(control Group)Other
No intervention
| Study group | Role | What they receive |
|---|---|---|
| Metastatic DTC | Not described Receives: Other: No additional drugs(control Group) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Measured: 5 years
Secondary outcomes (1)
Thyroid cancer-specific survival
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2025
- Study start1 Jan 1988
- Primary completion31 Dec 2018
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Differentiated Thyroid CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 178 participants (actual)
Sponsor and investigators
- Lead sponsor
- King Faisal Specialist Hospital & Research Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Khawla S. Al-Kuraya, King Faisal Specialist Hospital & Research Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07115810
- Sponsor's protocol ID
- RAC#2110031
- Status last verified
- Aug 2025
- First submitted
- 4 Aug 2025
- Last updated
- 11 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared due to local regulations in Saudi Arabia
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid Cancer: Insight From Middle Eastern Cohort
- ClinicalTrials.gov ID
- NCT07115810
- Acronym / sponsor ID
- RAC#2110031
- Conditions
- Differentiated Thyroid Cancer
- Keywords
- synchronous metastasis, metachronous metastasis, prognosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 178 participants (actual)
- Lead sponsor
- King Faisal Specialist Hospital & Research CenterUniversity, hospital or other
- Study start
- 1 Jan 1988 (actual)
- Primary completion
- 31 Dec 2018 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 11 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to compare the clinical outcomes, molecular features, and immune profiles of patients with synchronous and metachronous distant metastases in Saudi cohort with well characterized differentiated thyroid cancer. The main question it aims to answer is whether timing of metastasis is associated with distinct prognostic or biological behavior in differentiated thyroid cancer from a large Middle Eastern cohort
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Metastatic DTC | – | Other: No additional drugs(control Group) |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with metastatic differentiated thyroid cancer diagnosed at King Faisal Specialist Hospital \& Research Centre in Riyadh, Saudi Arabia
Key inclusion criteria (1 listed)
- Synchronous or metachronous distant metastases
Key exclusion criteria (2 listed)
- Not DTC
- No distant metastases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No additional drugs(control Group)No intervention | Other | Metastatic DTC |
Primary outcome
Overall survival
Time frame: 5 years
1 secondary outcome
Thyroid cancer-specific survival
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2025.
- Individual participant dataSharing planned: No. IPD will not be shared due to local regulations in Saudi Arabia
Related trials for Differentiated Thyroid Cancer
RecruitingPhase 2
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Differentiated Thyroid Carcinoma
Not yet recruitingObservational study
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
RecruitingPhase 2
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Thyroid Cancer
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
Enrolling by invitationPhase 3
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Cancer, Renal Cell Carcinoma (RCC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Differentiated Thyroid Cancer, run by King Faisal Specialist Hospital & Research Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2025.